Huge news for the Platelet Rich Plasma (PRP) world was just released. The Centers for Medicare and Medicaid Services (CMS) proposes that platelet-rich plasma (PRP) – an autologous blood-derived product, will be covered only for the treatment of chronic non-healing diabetic, venous and/or pressure wounds.
This is great news for potential PRP injection patients, PRP Treatments, PRP doctors and clinics and companies such as Cytomedix (CMXI).
We will be covering this story and updating THIS POST as more news comes out.
Update: CMXI stock has risen huge amounts since this news. A few months back it was .30 cents and now sits at $1.82 per share – it’s still on the rise.
Links related to PRP Approval by the CMS:
- CMS Decision Summary
- Yahoo Finance!
- CMXI Cytomedix Forum on Yahoo
- PRP Approved by CMS for Chronic Wounds
- CMS Coverage Big Positive For Cytomedix – Seeking Alpha
Follow us on Twitter for all the updates!
What PRP Experts are Saying about this CMS Coverage Decision
- Dr. Allan Mishra tweeted – “Preliminary coverage by CMS of platelet rich plasma for wounds will encourage research & development of new PRP applications”
